Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease

Increased Baseline TNF-Driven Pathways Observed in Patients with Crohn's Disease not Responding to Infliximab

(2017) Bram Verstockt et al.   GASTROENTEROLOGY

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

(2017) Fernando Magro et al.   Journal of Crohns & Colitis

Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases

(2016) Dario Sorrentino et al.   INFLAMMATORY BOWEL DISEASES

286 Drug Concentrations and Antibodies to Infliximab Are Inferior to the Impact of Disease Burden in Primary Non-Response to Infliximab in Crohn's Disease Patients

(2015) Thomas Billiet et al.   GASTROENTEROLOGY

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study

(2015) Andres J Yarur et al.   GUT

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

(2014) Niels Vande Casteele et al.   GUT

A Systematic Review of Measurement of Endoscopic Disease Activity and Mucosal Healing in Crohnʼs Disease

(2014) Reena Khanna et al.   INFLAMMATORY BOWEL DISEASES

In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

(2014) Raja Atreya et al.   NATURE MEDICINE

CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitis

(2013) Maria K Magnusson et al.   United European Gastroenterology Journal

Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy

(2011) S. Danese et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis

(2011) T. Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease

(2011) James D. Lewis   GASTROENTEROLOGY

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

(2011) Natalie A. Molodecky et al.   GASTROENTEROLOGY

Transmembrane TNF- : structure, function and interaction with anti-TNF agents

(2010) T. Horiuchi et al.   RHEUMATOLOGY

Diagnosis and assessment of Crohn’s disease: the present and the future

(2010) Gianluca Benevento et al.   Expert Review of Gastroenterology & Hepatology

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1β production and deficient apoptosis of rheumatoid arthritis monocytes

(2009) Undine Meusch et al.   ARTHRITIS AND RHEUMATISM

Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab

(2008) Hiroki Mitoma et al.   ARTHRITIS AND RHEUMATISM